DOCSLIB.ORG

Opioids and Antidepressants: Which Combinations to Avoid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioids and Antidepressants: Which Combinations to Avoid VOLUME 44 : NUMBER 2 : APRIL 2021 ARTICLE Opioids and antidepressants: which combinations to avoid Varan Perananthan SUMMARY Clinical pharmacology and toxicology advanced Some opioids such as tramadol, pethidine, dextromethorphan and tapentadol increase trainee1,2 serotonergic activity. Fentanyl and methadone also do this but to a lesser extent. Nicholas Buckley Consultant clinical These opioids may increase the risk of serotonin toxicity when combined with antidepressants. pharmacologist and Some selective serotonin reuptake inhibitors block the metabolism of opioids. This may reduce the toxicologist1 concentrations and analgesic effect of some opioids such as codeine and tramadol, and increase Professor of Clinical 2 the concentrations and risk of adverse effects of other opioids such as methadone. Pharmacology 1 Fluoxetine and irreversible monoamine oxidase inhibitors – tranylcypromine and phenelzine – Edith Collins Centre, Drug Health Services, Royal have prolonged actions and may interact for weeks after they have been discontinued. Prince Alfred Hospital, Sydney Introduction • autonomic hyperactivity – fevers, tachycardia, 2 School of Medical diaphoresis, tachypnoea Sciences, Biomedical Opioid dispensing increased fourfold in Australia Informatics and Digital from 1990 to 2014 and prescribing of antidepressants • altered mental state. Health, University of Sydney doubled from 2000 to 2016. The prescribing of Serotonin toxicity generally only occurs when both classes in combination is therefore increasingly serotonergic opioids are given with another Keywords 1,2 common. While many combinations have minimal risk, serotonergic drug such as an antidepressant, antidepressants, drug some may increase the risk of serotonergic effects and even at therapeutic doses (see Box).3 The highest interactions, monoamine other toxicity, or reduce analgesic efficacy. The simplest risk opioid drugs are tramadol, pethidine and oxidase inhibitors, opioids, preventive strategy is to generally avoid prescribing dextromethorphan.7 The highest risk serotonergic serotonin toxicity opioids associated with higher risks of interaction. drugs are the irreversible monoamine oxidase inhibitor (MAOI) antidepressants, tranylcypromine Aust Prescr 2021;44:41–4 Opioids and serotonergic activity and phenelzine.8 The risk and precautions with https://doi.org/10.18773/ The analgesic effect of opioids is mediated through three different combinations are summarised in the austprescr.2021.004 major opioid receptors – mu, delta and kappa. However, Table.3,6,7,9 The highest risk for serotonin toxicity by many opioids have actions on other targets, for example far is with irreversible MAOIs and pethidine, tramadol blocking serotonin and noradrenaline reuptake or dextromethorphan. and N-methyl-aspartate (NMDA) receptors.3 This is There have been occasional case reports of mostly a phenomenon with synthetic opioids. These serotonin toxicity with low-risk opioid and additional actions may be beneficial or harmful and antidepressant combinations, such as oxycodone occur peripherally and in the central nervous system.3 and buprenorphine/naloxone (Suboxone) with Serotonin in the neuronal synapse is tightly regulated other serotonergic medicines.10-13 Many of these via multiple mechanisms – a key one involves the reports have very obvious alternative medical serotonin transporter. Some opioids inhibit the explanations for all the signs of the alleged severe serotonin transporter which increases concentrations serotonin toxicity.14 However, it also seems likely that of serotonin in the synaptic cleft and therefore moderate serotonin toxicity may occasionally be postsynaptic serotonin signalling.4,5 precipitated by any opioid in susceptible individuals taking an antidepressant, perhaps due to indirect Toxicity effects of opioids on serotonin release. A high Serotonin toxicity or syndrome results from excessive index of suspicion is therefore needed.8 Similarly, serotonin and its severity depends on the amount of antidepressants such as agomelatine, mianserin and 6 excess serotonin. The three main groups of features are: reboxetine have a very low risk of serotonin syndrome • neuromuscular hyperactivity – clonus, myoclonus, but caution still might be warranted in combination tremor, hyperreflexia, rigidity with very high-risk serotonergic drugs.3,5,7 © 2021 NPS MedicineWise Full text free online at nps.org.au/australian-prescriber 41 VOLUME 44 : NUMBER 2 : APRIL 2021 ARTICLE Opioids and antidepressants: which combinations to avoid Box Drugs likely to increase the risk of serotonin toxicity Inhibition of opioid metabolism when combined with serotonergic opioids3 The two most commonly used ‘weak opioids’ codeine and tramadol require cytochrome P450 (CYP) 2D6 Monoamine oxidase inhibitors for conversion to an active opioid agonist. They • irreversible inhibitors (phenelzine, tranylcypromine) consequently have less abuse potential which • reversible inhibitors of monoamine oxidase (moclobemide) allows less restrictive scheduling in most countries. However, many antidepressants are CYP2D6 inhibitors • non-antidepressant monoamine oxidase inhibitors (linezolid, methylene blue, lamotrigine) (fluoxetine, paroxetine, and to a lesser extent Serotonin-releasing drugs duloxetine, fluvoxamine, sertraline, desvenlafaxine and • appetite suppressants (fenfluramine, sibutramine) escitalopram). This means combinations of codeine • amphetamines (methamphetamine, methylphenidate, phentermine) or tramadol with these antidepressants may lead to • synthetic stimulants (MDMA, cathinones) reduced analgesia.15 Serotonin reuptake inhibitors Conversely, inhibition of metabolism of other opioids • selective serotonin reuptake inhibitors (via a variety of enzymes) may lead to increased risks • serotonin noradrenaline reuptake inhibitors of opioid adverse effects. The combinations that are particularly of concern are specific to individual drugs • tricyclic antidepressants (clomipramine, imipramine) such as tramadol, tapentadol, fentanyl and methadone. • serotonin modulators (vortioxetine) Miscellaneous Tramadol • lithium While tramadol’s main metabolite is an opioid agonist, • St John’s wort it is remarkably similar in structure to venlafaxine, • tryptophan with similar inhibitory effects on noradrenaline and 16,17 • buspirone serotonin reuptake. The combination of tramadol with an antidepressant is by far the most common • triptans serotonergic drug–drug interaction.18,19 As tramadol inhibits serotonin and noradrenaline MDMA 3,4-methylenedioxymethamphetamine reuptake, combinations with selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) are likely to have additional adverse effects without added benefits. Inhibition Table The risk of serotonergic toxicity with combinations of CYP2D6 by common antidepressants such as 3,6,7,9 of antidepressants and opioids paroxetine and fluoxetine20 not only reduces conversion of tramadol to an opioid agonist, it also results Antidepressants in higher concentrations of tramadol. Thus, these Low–intermediate risk High risk antidepressants both directly and indirectly increase SSRIs, SNRIs, TCAs, MAOIs (or previous history the serotonergic and other adverse effects of tramadol, Opioids St John’s wort, lithium of serotonin toxicity) while potentially reducing analgesic efficacy.16,21 Low risk Should be safe Possible rare interaction. Seizures are a key adverse effect of tramadol and Use with caution Morphine, codeine,* can occur in overdose.22 Tramadol is also commonly buprenorphine, implicated in new onset seizures with therapeutic oxymorphone, use.23 This risk is further heightened when it is hydromorphone, oxycodone co-administered with SSRIs, tricyclic antidepressants, venlafaxine and bupropion.21,24-26 Medium risk Possible rare interaction. Increased risk of serotonin Fentanyl, tapentadol, Use with caution syndrome Tapentadol methadone Tapentadol has different pharmacology to tramadol. High risk Increased risk of serotonin Contraindicated It is an opioid agonist without active metabolites Tramadol,* pethidine, syndrome and a noradrenaline reuptake inhibitor with only dextromethorphan weak effects on serotonin reuptake.27 MAOI use is contraindicated with tapentadol and there have been * risk of decreased analgesic effect many reports to regulatory agencies of serotonin SSRI selective serotonin reuptake inhibitor toxicity with this combination.7 MAOIs were also SNRI serotonin noradrenaline reuptake inhibitor 9 TCA tricyclic antidepressant excluded from most tapentadol trials. Currently, it is MAOI monoamine oxidase inhibitor unclear if tapentadol has a greater risk of serotonin toxicity than other opioids. 42 Full text free online at nps.org.au/australian-prescriber VOLUME 44 : NUMBER 2 : APRIL 2021 ARTICLE Fentanyl Other drug interactions Fentanyl is a high-potency opioid agonist with no Sedating antidepressants such as tricyclics, tetracylics effect on serotonin reuptake and low affinity (relative (mirtazepine and mianserin) and agomelatine to opioid receptor affinity) for postsynaptic serotonin in combination with opioids can exacerbate 5 receptors (5-HT1A and 5-HT2A). Co-administration drowsiness which can increase the risk of falls and with an SSRI has been reported to cause an agitated respiratory depression.30 28 delirium consistent with serotonin toxicity. However, Serotonergic drug interactions are not confined in a retrospective analysis of 4583 people who to antidepressants and opioids. For example, very
Load more

Recommended publications
  • An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. P
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 17 November 2020 doi:10.20944/preprints202011.0443.v1 An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. Pande1, Brian J. Piper1,2* 1Department of Medical Education, Geisinger Commonwealth School of Medicine 2Center for Pharmacy Innovation and Outcomes * Brian J. Piper, Ph.D.525 Pine Street, Geisinger Commonwealth School of Medicine Scranton, PA 18411, USA Abstract: Buprenorphine, an analogue of thebaine, is a Schedule III opioid in the United States used for opioid-use disorder and as an analgesic. Research has shown drugs like buprenorphine have a complicated pharmacology with characteristics that challenge traditional definitions of terms like agonist, antagonist, and efficacy. Buprenorphine has a high affinity for the mu (MOR), delta (DOR), kappa (KOR), and intermediate for the nociceptin opioid receptors (NOR). Buprenorphine is generally described as a partial MOR agonist with limited activity and decreased response at the mu- receptor relative to full agonists. In opioid naïve patients, the drug’s analgesic efficacy is equivalent to a full MOR agonist, despite decreased receptor occupancy and the “ceiling effect” produced from larger doses. Some argue buprenorphine’s effects depend on the endpoint measured, as it functions as a partial agonist for respiratory depression, but a full-agonist for pain. Buprenorphine’s active metabolite, norbuprenorphine, attenuates buprenorphine's analgesic effects due to NOR binding and respiratory depressant effects. The method of administration impacts efficacy and tolerance when administered for analgesia. There have been eleven-thousand reports involving buprenorphine and minors (age < 19) to US poison control centers, the preponderance (89.2%) with children.
    [Show full text]
  • A Quick Guide to Drugs and Alcohol
    A QUICK GUIDE TO Drugs & Alcohol THIRD EDITION by the National Drug and Alcohol Research Centre (NDARC) Drug Info is a partnership between the State Library of New South Wales and NSW Health. www.druginfo.sl.nsw.gov.au Disclaimer The contents of this book are intended for information purposes only. Every efort has been made to ensure that the information is correct at the time of publication. Drug Info does not ofer any information in this book as a tool for treatment, counselling or legal advice. Drug Info recommends that prior to making any decision based on any information in this book, you should obtain independent professional legal or medical advice. Websites and information about service providers referred to in the publication have been selected to provide relevant and up-to-date information as at the date of publication. Drug Info accepts no responsibility for the content of websites and does not endorse any specifc services ofered by providers. A Quick Guide to Drugs & Alcohol, third edition, September 2017 Published by Drug Info, State Library of NSW © Copyright Library Council of NSW and NSW Ministry of Health, 2017 ISBN 0 7313 7239 5 (print) ISBN 0 7313 7240 9 (online) Printed in Australia by SEED Print, using Spicers Paper Monza Recycled Satin 350 gsm and Impress Matt 115 gsm. Monza Recycled contains 99% recycled fbre and is FSC® Mix Certifed, Impress Matt is FSC® Mix Certifed. P&D-4660-9/2017 ECSTASY E, pills, eccy, XTC, MDMA, pingas, Adam, X 7 Ecstasy is a derivative of methamphetamine (the active ingredient is 3, 4-methylenedioxymethamphetamine, abbreviated to MDMA).
    [Show full text]
  • Tramadol (Ultram)
    TRAMADOL (ULTRAM) Tramadol is FDA approved for the treatment of musculoskeletal pain. Studies have shown it is useful in treating the pain associated with diabetic neuropathy and other pain conditions. Tramadol comes in 50 mg tablets. The maximum dose is two tablets four times per day unless your kidney function is below normal or you are over 75 years old, in which case the maximum dose is two tablets three times per day. The main side effects of Tramadol are drowsiness, sedation, and stomach upset, all of which are minimized by slowly raising the dose. About 5% of patients have stomach upset at any dose of Tramadol and cannot take the medicine. Other risks include seizures (occur in less than 1/100,000 and are more likely if you have seizures) and possibly abuse (relevant if you have abused drugs in the past). Tramadol should be started at a low dose and raise the dose slowly toward the maximum dose. Start with one tablet at bedtime. After 3 - 7 days, increase to one tablet twice daily (morning and bedtime). After an additional 3 - 7 days, increase to one tablet three times per day (morning, noon, and bedtime). After an additional 3 - 7 days, increase to one tablet four times per day (1 tablet with each meal and 1 at bedtime). At that point, the dose may be increased or adjusted depending on how you are doing. To increase further, you will: Add a second tablet at bedtime (one tablet three times per day and two tablets at bedtime). After 3 - 7 days, add a second tablet to another dose (one tablet twice per day and two tablets twice per day).
    [Show full text]
  • Effects of Prophylactic Ketamine and Pethidine to Control Postanesthetic Shivering: a Comparative Study
    Biomedical Research and Therapy, 5(12):2898-2903 Original Research Effects of prophylactic ketamine and pethidine to control postanesthetic shivering: A comparative study Masoum Khoshfetrat1, Ali Rosom Jalali2, Gholamreza Komeili3, Aliakbar Keykha4;∗ ABSTRACT Background: Shivering is an undesirable complication following general anesthesia and spinal anesthesia, whose early control can reduce postoperative metabolic and respiratory complications. Therefore, this study aims to compare the effects of prophylactic injection of ketamine and pethi- dine on postoperative shivering.Methods: This double-blind clinical trial was performed on 105 patients with short-term orthopedic and ENT surgery. The patients were randomly divided into three groups; 20 minutes before the end of the surgery, 0.4 mg/kg of pethidine was injected to the first group, 0.5 mg/kg of ketamine was injected to the second group, and normal saline was injected to the third group. After the surgery, the tympanic membrane temperature was measured at 0, 10, 20, and 30 minutes. The shivering was also measured by a four-point grading from zero (no shiv- ering) to four (severe shivering). Data were analyzed by one-way ANOVA, Kruskal Wallis, Chi-square 1Doctor of Medicine (MD), Fellow of and Pearson correlation. Results: The mean age of patients was 35.811.45 years in the ketamine Critical Care Medicine (FCCM), group, 34.811.64 years in the normal saline group, and 33.1110.5 years in the pethidine group. Department of Anesthesiology and The one-way ANOVA showed no significant difference in the mean age between the three groups Critical Care, Khatam-Al-Anbiya (P=0.645).
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 CONTENTS General Toxicology 9 Metals 38 Management 21 Pesticides 41 Drugs 23 Chemical Warfare 42 Chemical Incidents & 32 Plants 43 Pollution Chemicals 33 Animals 43 CURRENT AWARENESS PAPERS OF THE MONTH How toxic is ibogaine? Litjens RPW, Brunt TM. Clin Toxicol 2016; online early: doi: 10.3109/15563650.2016.1138226: Context Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. Objectives To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. Methods A search of the literature available on PubMed was done, using the keywords "ibogaine" and "noribogaine". The search criteria were "mechanism of action", "pharmacokinetics", "pharmacodynamics", "neurotransmitters", "toxicology", "toxicity", "cardiac", "neurotoxic", "human data", "animal data", "addiction", "anti-addictive", "withdrawal", "death" and "fatalities". The searches identified 382 unique references, of which 156 involved human data. Further research revealed 14 detailed toxicological case reports. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Use of Analgesics in Exotic Felids Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University Of
    Use of Analgesics in Exotic Felids Formatted: Centered Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University of Tennessee, and Consulting Veterinarian, Knoxville Zoological Gardens, Knoxville, Tennessee. Corresponding address: Ed Ramsay Dept. of Sm Animal Clin Sci C247, Veterinary Teaching Hospital University of Tennessee Knoxville, TN 37996-4544 Phone: 865-755-8219 FAX: 865-974-5554 Email: [email protected] 2 Treatment of pain in domestic and non-domestic cats has been a challenge for the clinician. Many cat species are stoic and show few or very subtle external signs of pain. Additionally, the adverse effects of nonsteroidal antiinflammatory drugs (NSAIDs) in domestic cats are well documented and have discouraged many practitioners from trying novel NSAID’s in exotic felids. As in other animals, each cat’s response to pain and analgesics will vary, necessitating an individualized treatment plan. As a rule, always treat painful felids to effect, and not by rote reliance on published dosages. It is frequently necessary to try different agents and combinations to find which produces the optimal analgesic effect in exotic felids. In order to minimize adverse effects, it is desirable to work toward treatment with the lowest effective dose when treating chronic pain. Non-steroidal Antiinflammatory Drugs NSAIDs are antiinflammatory drugs which act both centrally and peripherally. The primary effects are believed to be caused by their ability to inhibit cyclooxygenase (COX) enzymes in the arachidonic acid metabolism cascade. The COX-1 isoform is regarded as constitutive (continuously expressed) and is responsible for many homeostatic processes, such as maintenance of gastric mucosal integrity, platelet function, and renal autoregulation.
    [Show full text]
  • Dezocine Exhibits Antihypersensitivity Activities in Neuropathy Through
    www.nature.com/scientificreports OPEN Dezocine exhibits antihypersensitivity activities in neuropathy through spinal Received: 09 November 2016 Accepted: 19 January 2017 μ-opioid receptor activation and Published: 23 February 2017 norepinephrine reuptake inhibition Yong-Xiang Wang1, Xiao-Fang Mao1, Teng-Fei Li1, Nian Gong1 & Ma-Zhong Zhang2 Dezocine is the number one opioid painkiller prescribed and sold in China, occupying 44% of the nation’s opioid analgesics market today and far ahead of the gold-standard morphine. We discovered the mechanisms underlying dezocine antihypersensitivity activity and assessed their implications to antihypersensitivity tolerance. Dezocine, given subcutaneously in spinal nerve-ligated neuropathic rats, time- and dose-dependently produced mechanical antiallodynia and thermal antihyperalgesia, significantly increased ipsilateral spinal norepinephrine and serotonin levels, and induced less antiallodynic tolerance than morphine. Its mechanical antiallodynia was partially (40% or 60%) and completely (100%) attenuated by spinal μ-opioid receptor (MOR) antagonism or norepinephrine depletion/α2-adrenoceptor antagonism and combined antagonism of MORs and α2-adenoceptors, respectively. In contrast, antagonism of spinal κ-opioid receptors (KORs) and δ-opioid receptors (DORs) or depletion of spinal serotonin did not significantly alter dezocine antiallodynia. In addition, dezocine- delayed antiallodynic tolerance was accelerated by spinal norepinephrine depletion/α2-adenoceptor antagonism. Thus dezocine produces antihypersensitivity activity through spinal MOR activation and norepinephrine reuptake inhibition (NRI), but apparently not through spinal KOR and DOR activation, serotonin reuptake inhibition or other mechanisms. Our findings reclassify dezocine as the first analgesic of the recently proposed MOR-NRI, and reveal its potential as an alternative to as well as concurrent use with morphine in treating pain.
    [Show full text]
  • Quantitative Drug Test Menu Section 2
    1 Guthrie Square, Sayre, PA 18840 Bill To: Client GMG Toxicology Laboratory Requisition Toll Free Phone (844) 617-4719 Insurance Request Date: _____/______/______ Medical Director: Hani Hojjati, MD Fax (570) 887-4729 Patient PATIENT INFORMATION (PLEASE PRINT IN BLACK INK) INSURANCE BILLING INFORMATION (PLEASE PRINT IN BLACK INK) Pt Last Name First M I PRIMARY Medicare Medicaid Other Ins. Self Spouse Child __ Subscriber Last Name First M Address Birth Date Sex M F Beneficiary/Member # Group # City Pt. SS# or MRN Claims Name and Address City ST ZIP ST ZIP Home Phone (Attach a copy of the patient's insurance card and information) SECONDARY Medicare Medicaid Other Ins. Self Spouse Child Employer Work Phone Subscriber Last Name First M Work Address City ST ZIP Beneficiary/Member # Group # __ CLIENT INFORMATION - REFERRING PHYSICIAN Claims Name and Address City ST ZIP Client Address: (Atttach a copy of the patient's insurance card and information) COLLECTION / REPORTING INFORMATION Copy to: FAX Results to __ CALL Results to Phone: Fax: Date Collected: Time Collected: AM PM Specimen Type: Urine Saliva Other ___________________ Physician Signature (legible - No Stamp) For Lab Use Only (Required for Medicare & Medicaid patient orders) Signed ABN Obtained Place Lab Label Here Contact Laboratory Medical Director (570-887-4719) with questions concerning medical necessity PHYSICIAN When ordering tests, the physician is required to make an independent medical necessity decision with regard to each test thelaboratory will bill. The physician also understands he or she is required NOTICE to (1) submit ICD-10 diagnosis supported in the patient's medical record as documentation of the medical necessity or (2) explain and have the patient sign an ABN.
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Recommendations for Prescribing Analgesia on Discharge Following Surgery Or Acute Injury Information for Health Practitioners Preparing the Patient for Discharge
    Recommendations for prescribing analgesia on discharge following surgery or acute injury Information for health practitioners preparing the patient for discharge better health * better care * better value This booklet ‘Recommendations for prescribing analgesia on discharge following surgery or acute injury: Information for health practitioners preparing the patient for discharge’ is designed to be used in conjunction with the patient booklet titled ‘Pain relief medications following surgery and injury: Information for patients preparing for discharge’. Developed by the Analgesia Management Working Group (AMWG) and made available by the Western Australian Medication Safety Group (WAMSG). For more information on the WAMSG or this booklet go to website www.watag.org.au/wamsg Disclaimer: The information contained in this brochure has been produced as a guide only. It is not intended to be comprehensive and does not take the place of professional medical advice from your doctor, nurse or pharmacist. Contents Background 2 Recommendations for prescribing post-operative analgesia for pain following an acute injury or surgery 4 Precautions when prescribing opioids with other medications 6 Recommendations for prescribing discharge analgesia for pain following an acute injury or surgery 8 Paracetamol 8 Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 8 Opioids 8 Communication to the primary care provider 10 Communication with the patient 10 Appendix 1 – Post-operative and post-intervention analgesia discharge checklist 11 Appendix 2 – Discharge analgesic plan 13 References 14 Recommendations for prescribing analgesia on discharge following surgery or acute injury | 1 Background The WA Medication Safety Group (WAMSG) has identified analgesia management post- surgery or acute injury (specifically managing and ceasing opioids), in the transition period from hospital to home, as a priority safety issue for patients and the community.
    [Show full text]
  • Codeine: the Facts Suzanne Nielsen Bpharm Phd MPS Codeine: Overview 1
    Codeine: The facts Suzanne Nielsen BPharm PhD MPS Codeine: overview 1. Codeine use in Australia 2. Characteristics of codeine dependence 3. Identifying codeine dependence 4. Treatment approaches (focus on primary care) 2 Codeine use in Australia Codeine (OTC) Tramadol Tapentadol Dextropropoxyphene Codeine (prescription) Oxycodone Morphine Methadone Hydromorphone Fentanyl Buprenorphine 0 5 10 15 20 Million packs Opioid pack sales (in millions) from: Degenhardt, Gisev, Cama, Nielsen, Larance and Bruno. The extent and predictors of pharmaceutical opioid utilisation in Australia. Pharmacoepidemiology and Drug Safety. (2016) 3 Codeine use in Australia • > 15 million packs OTC and 12 million prescribed • Highest codeine use in remote areas and low income areas 4 Codeine as an analgesic • Weak mu-opioid agonist • Analgesic effect predominantly through its metabolism to morphine via CYP2D6 enzyme • Considerable variable in metabolism between individuals (from poor to ultra-rapid metabolism) • Ultra-rapid metabolism opioid toxicity • Poor metabolism no analgesic effect Kirchheiner J et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.Pharmacogenomics J. 2007 5 Codeine-related harm • Codeine-related deaths increased from 3.5 per million in 2000 to 8.7 per million in 2009 • Trebling of non-OST drug treatment presentations fpr codeine between 2002-2011 • Among people entering methadone and buprenorphine increasing numbers report codeine as the main drug • 2014 – 2.7% of cases (1287 people) • 2015 – 3.5% of cases (1676 people) • 2016 – 4.6% of cases (1562 people*) * missing data from Vic and ACT means actual number likely to be higher (>2000) Roxburgh et al (2015). Medical Journal of Australia.
    [Show full text]